<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947102</url>
  </required_header>
  <id_info>
    <org_study_id>Gemcitabine1</org_study_id>
    <nct_id>NCT00947102</nct_id>
  </id_info>
  <brief_title>Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer</brief_title>
  <acronym>GEMSTHER</acronym>
  <official_title>Observational Study - Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Tubular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blood Transfusion Centre of Slovenia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Blood Transfusion Centre of Slovenia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study of influence of gemcitabine treatment on serological and immunological
      status and gene expression profile in patients with pancreatic tubular carcinoma after tumor
      resection.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <condition>Pancreatic Tubular Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Pancreatic tubular adenocarcinoma</arm_group_label>
    <description>Patients with pancreatic tubular adenocarcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <arm_group_label>Pancreatic tubular adenocarcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients after resection of pancreatic tubular adenocarcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG performance status 0-2 at the time of inclusion

          -  Following R0 or R1 pancreatic tubular adenocarcinoma resection

        Exclusion Criteria:

          -  Pregnancy

          -  Serious comorbidity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Borut Stabuc, MD, PhD</last_name>
    <phone>+386 1 522 22 10</phone>
    <email>borut.stabuc@kclj.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lojze Smid, MD</last_name>
    <email>lojze.smid.jr@mf.uni-lj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana; Department for Gastroenterology</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Borut Stabuc, MD, PhD</last_name>
      <phone>+386 1 522 2210</phone>
      <email>borut.stabuc@kclj.si</email>
    </contact>
    <contact_backup>
      <last_name>Lojze Smid, MD</last_name>
      <email>lojze.smid.jr@mf.uni-lj.si</email>
    </contact_backup>
    <investigator>
      <last_name>Borut Stabuc, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2009</study_first_submitted>
  <study_first_submitted_qc>July 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2009</study_first_posted>
  <last_update_submitted>January 12, 2010</last_update_submitted>
  <last_update_submitted_qc>January 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Primoz Rozman MD, PhD</name_title>
    <organization>Blood Transfusion Centre of Ljubljana</organization>
  </responsible_party>
  <keyword>pancreatic tubular adenocarcinoma</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>gene expression</keyword>
  <keyword>immunological status</keyword>
  <keyword>serological status</keyword>
  <keyword>pancreatic tubular adenocarcinoma adjuvant setting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

